These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 33301)

  • 1. [Bacterial polysaccharides--a new generation of vaccines].
    Kaijser B
    Lakartidningen; 1979 Jan; 76(1-2):41-2. PubMed ID: 33301
    [No Abstract]   [Full Text] [Related]  

  • 2. [Bacterial polysaccharide vaccines: Meningococcus, Pneumococcus, Haemophilus influenzae].
    Triau R
    Rev Prat; 1984 Jun; 34(31):1683-90. PubMed ID: 6429835
    [No Abstract]   [Full Text] [Related]  

  • 3. [Emphasis on bacterial vaccines].
    Huet M
    Arch Inst Pasteur Tunis; 1982 Dec; 59(4):481-93. PubMed ID: 6820928
    [No Abstract]   [Full Text] [Related]  

  • 4. Immune responses to polysaccharides: lessons from humans and mice.
    González-Fernández A; Faro J; Fernández C
    Vaccine; 2008 Jan; 26(3):292-300. PubMed ID: 18160186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of new bacterial vaccines in children.
    Klein JO
    Isr J Med Sci; 1983 Nov; 19(11):1026-9. PubMed ID: 6420367
    [No Abstract]   [Full Text] [Related]  

  • 6. New bacterial vaccines.
    Mäkelä PH
    Pediatr Infect Dis; 1982; 1(5):291-4. PubMed ID: 6818533
    [No Abstract]   [Full Text] [Related]  

  • 7. Prevention of bacterial meningitis. Vaccines and chemoprophylaxis.
    Lieberman JM; Greenberg DP; Ward JI
    Infect Dis Clin North Am; 1990 Dec; 4(4):703-29. PubMed ID: 2126022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contribution of bacterial cell wall compounds to airway hyperreactivity.
    Schreurs AJ; Nijkamp FP
    Eur J Respir Dis Suppl; 1984; 135():164-7. PubMed ID: 6329802
    [No Abstract]   [Full Text] [Related]  

  • 9. [New vaccines].
    Ozişik A; Ustaçelebi S
    Mikrobiyol Bul; 1992 Jan; 26(1):82-9. PubMed ID: 1574025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunologic considerations for the development of conjugate vaccines.
    Garner CV; Pier GB
    Contrib Microbiol Immunol; 1989; 10():11-7. PubMed ID: 2510971
    [No Abstract]   [Full Text] [Related]  

  • 11. Laboratory studies on oxacillin. I. In vitro activity against staphylococci and some other bacterial pathogens. II. Absorption and urinary excretion in normal young men.
    KLEIN JO; SABATH LD; FINLAND M
    Am J Med Sci; 1963 Apr; 245():399-412. PubMed ID: 14033374
    [No Abstract]   [Full Text] [Related]  

  • 12. Different meningitis-causing bacteria induce distinct inflammatory responses on interaction with cells of the human meninges.
    Fowler MI; Weller RO; Heckels JE; Christodoulides M
    Cell Microbiol; 2004 Jun; 6(6):555-67. PubMed ID: 15104596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunization of humans with polysaccharide vaccines induces systemic, predominantly polymeric IgA2-subclass antibody responses.
    Tarkowski A; Lue C; Moldoveanu Z; Kiyono H; McGhee JR; Mestecky J
    J Immunol; 1990 May; 144(10):3770-8. PubMed ID: 2110213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The capsular polysaccharide of group B Neisseria meningitidis as a vehicle for vaccine development.
    Jennings HJ
    Contrib Microbiol Immunol; 1989; 10():151-65. PubMed ID: 2479499
    [No Abstract]   [Full Text] [Related]  

  • 15. [Identification of Haemophilus influenzae, Streptococcus pneumoniae and Neisseria meningitidis by polymerase chain reaction].
    Parra E; Castañeda E; Moreno J
    Biomedica; 2007 Sep; 27(3):454-60. PubMed ID: 18320111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serologic responses to an Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine in very young Gambian infants.
    Campbell H; Byass P; Ahonkhai VI; Vella PP; Greenwood BM
    Pediatrics; 1990 Jul; 86(1):102-7. PubMed ID: 2113671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microbiologic effect of bovine cerebrospinal fluid and azithromycin against Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae.
    Destache CJ; Pakiz CB; Kersting K
    Pharmacotherapy; 1997; 17(5):985-9. PubMed ID: 9324186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, tolerability, and immunogenicity of concurrent administration of Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) with either measles-mumps-rubella vaccine or diphtheria-tetanus-pertussis and oral poliovirus vaccines in 14- to 23-month-old infants.
    Dashefsky B; Wald E; Guerra N; Byers C
    Pediatrics; 1990 Apr; 85(4 Pt 2):682-9. PubMed ID: 2107519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of animal testing for evaluating glycoconjugate vaccine immunogenicity.
    Madore DV; Strong N; Eby R
    Dev Biol Stand; 1999; 101():49-56. PubMed ID: 10566775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contemporary trends in conjugate vaccine development.
    Cruse JM; Lewis RE
    Contrib Microbiol Immunol; 1989; 10():1-10. PubMed ID: 2510970
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.